Simple new blood test could help identify Parkinson's patients at early stages of disease
A simple blood test may help identify people at the earliest stages of Parkinson's disease, long before they begin to show symptoms, new research has found.
The study, published on Friday in the journal Nature Aging, is the latest to identify early warning signs of Parkinson's, a neurodegenerative condition that affects about 10 million people worldwide and occurs when the brain slowly stops producing the chemical dopamine in areas that control movement and balance.
There is no cure for Parkinson's, which causes tremors, stiffness, slow movement, and cognitive impairment.
Most people are diagnosed based on these symptoms, but by that point, more than 60 per cent of dopamine neurons have already degraded – which is why scientists are hunting for ways to diagnose patients earlier.
For the new study, Israeli researchers compared blood and brain tissue data between Parkinson's patients and those in good health.
Related
Parkinson's cases could double by 2050, reaching 25 million worldwide
They focused on small RNA molecules known as transfer RNA fragments (tRFs), which appear to play a role in neurological issues such as Parkinson's.
Two key biomarkers emerged; one that's linked to Parkinson's and another to the progression of the disease. Using a blood test to measure the distance between them could serve as an additional early diagnostic for the condition, the findings suggest.
'By focusing on tRFs, we've opened a new window into the molecular changes that occur in the earliest stages of the disease,' said Hermona Soreq, one of the study's authors and a professor of molecular neuroscience at the Hebrew University of Jerusalem.
But the researchers said bigger studies that follow a more diverse group of Parkinson's patients over time are needed to confirm their results and understand how changes to these biomarkers affect patient outcomes.
Related
Diabetes drug similar to Ozempic showed no benefits for patients with Parkinson's disease
It's also not clear whether the blood test would be able to differentiate between Parkinson's and other conditions with similar early symptoms.
'More work is needed to continue to test and validate this possible test, especially understanding how it can distinguish between other conditions that have similar early signs to Parkinson's,' David Dexter, director of research at Parkinson's UK, told Euronews Health.
'This research represents a new angle to explore in the search for a biological marker for Parkinson's,' added Dexter, who was not involved with the study.
Related
Reducing air pollution exposure could curb Parkinson's risks, researchers say
Other scientists have found additional biomarkers of interest.
One EU-funded study published last year identified eight proteins in the blood that could help identify Parkinson's patients up to seven years before major symptoms appear.
The prospect of a quick, reliable blood test for Parkinson's could 'alleviate the burden of uncertainty from suffering individuals, assist clinicians' care of those patients early in the disease process and open routes for developing and testing new therapeutics,' the Israeli researchers said.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Bloomberg
41 minutes ago
- Bloomberg
EU Poised to Curb China's Access to Medical Device Procurement
The European Union is set to curb Chinese medical device manufacturers' access to public procurement contracts in the bloc, according to a person familiar with the matter. EU countries are due to vote on the proposed measure as early as Monday, said the person, who spoke on condition of anonymity to discuss private deliberations.
Yahoo
an hour ago
- Yahoo
Press Release Biocartis NV: Biocartis Announces IVDR Class C CDx Certification of the Idylla™ EGFR Mutation Test
PRESS RELEASE 02/06/2025, 10:00 CEST Biocartis Announces IVDR Class C CDx Certification of the Idylla™ EGFR Mutation Test Mechelen, Belgium, 02 June 2025 – Biocartis NV ('Biocartis'), an innovative molecular diagnostics company, is pleased to announce that its Idylla™ EGFR Mutation Test has received the European Union (EU) Technical Documentation Assessment and Quality Management System certificate under the European In Vitro Diagnostic Medical Device Regulation (EU) 2017/746 (IVDR), making it the first Idylla™ Test to be certified as a Class C Companion Diagnostic (CDx) IVD Medical Device under the IVDR framework. The IVDR-certified Idylla™ EGFR Mutation Test is designed to serve as a CDx for the detection of EGFR exon 19 deletions and the L858R mutation, which are key biomarkers that guide targeted therapies for patients with non-small cell lung cancer (NSCLC). The IVDR certification confirms the Test's compliance with Europe's rigorous new regulatory standards, ensuring enhanced patient safety, improved information transparency, and robust data traceability. Designed for use on the Idylla™ Platform, the Test qualitatively detects 44 mutations across exons 18, 19, 20, and 21 of the EGFR gene – all within a single cartridge. Among these, exon 19 deletions and L858R mutations are validated as CDx targets, and the remaining mutations have been analytically validated. Utilizing formalin-fixed, paraffin-embedded (FFPE) tissue samples, the Test is fully automated from sample to result, delivering fast results in under 3 hours – streamlining laboratory workflows and empowering oncologists with timely treatment decisions for their patients. With 99.2% sensitivity (PPA) and 99.0% specificity (NPA) for the CDx targets, the Idylla™ EGFR Mutation Test ensures accurate detection of key EGFR mutations, providing healthcare professionals with actionable results to guide treatment decisions in NSCLC. For more information about the Test, please visit the Biocartis website or contact the Biocartis team. While the IVDR-certified Idylla™ EGFR Mutation Test is now available to customers across Europe, with availability in other non-US markets expected to follow progressively – Biocartis is also developing the Idylla™ EGFR CDx Test in the US with AstraZeneca. Upon approval, the Test will be intended to help identify patients with NSCLC who may respond to treatment with Tagrisso® (Osimertinib), AstraZeneca's third-generation EGFR-TKI treatment. Roger Moody, Chief Executive Officer of Biocartis, commented: 'Achieving IVDR certification for our Idylla™ EGFR Mutation Test is a key milestone for Biocartis and reinforces our commitment to quality and regulatory excellence. This is the first Idylla™ Test to be certified under the new IVDR framework, and we are currently pursuing certification of additional Tests in our portfolio. The IVDR establishes more rigorous standards to improve patient safety and diagnostic accuracy, and we are proud to be at the forefront of this evolution in European diagnostics.' ----- END ----- More information: info@ Biocartis NV. Generaal De Wittelaan 11B, 2800 Mechelen, Belgium About Biocartis With its revolutionary and proprietary Idylla™ Platform, Biocartis aspires to enable personalized medicine for patients around the world through universal access to molecular testing, by making molecular testing actionable, easy, fast and suitable for any lab. The Idylla™ Platform is a fully automated sample-to-result, real-time PCR (Polymerase Chain Reaction) based system designed to offer in-house molecular biomarker testing in only 3 hours, allowing fast and optimal treatment selection. Idylla™'s continuously expanding menu of molecular diagnostic tests and research assays addresses key unmet clinical needs. Today, Biocartis offers tests supporting lung, skin, thyroid, colorectal, endometrial, blood, brain and breast cancer. More information: Follow us on LinkedIn, Facebook and X (Twitter). Disclaimers Idylla™ Platform is CE-marked in Europe in compliance with EU IVD Regulation 2017/746, listed as a class II device in the US under establishment registration 3009972873, and registered in many other countries. Idylla™ EGFR Mutation Test (A0270/6) is CE-marked in Europe in compliance with the EU IVD Regulation 2017/746 (IVDR). Biocartis and Idylla™ are registered trademarks in Europe, the US and many other countries. The Biocartis and Idylla™ trademarks and logos are used trademarks owned by Biocartis NV. © June 2025, Biocartis NV. All rights lors de la récupération des données Connectez-vous pour accéder à votre portefeuille Erreur lors de la récupération des données Erreur lors de la récupération des données Erreur lors de la récupération des données Erreur lors de la récupération des données
Yahoo
15 hours ago
- Yahoo
KONTAKTUM (former Berger Kommunkation) launches SignalDesk to Power Europe's Top Wellness Brands
BERLIN, June 01, 2025 (GLOBE NEWSWIRE) -- After more than 15 years operating quietly under the name BERGER KOMMUNIKATION, one of Europe's most trusted backend communication infrastructures has officially rebranded and relaunched as will now operate independently, with a sharpened focus on the wellness and health supplement industry across the EU. The new identity reflects the company's deep specialization in backend revenue systems — from multilingual customer support to advanced sales reactivation flows — for brands that ship thousands of units daily across Europe. While BERGER KOMMUNIKATION built its name in high-performance outbound operations, KONTAKTUM expands the model into a more modern, full-stack backend solution. That includes welcome call systems, cart recovery outreach, localized reactivation campaigns, and multilingual voice support — all designed to improve customer lifetime value (LTV) without disrupting frontend operations. 'Most brands focus on acquisition,' says a KONTAKTUM team lead. 'But the real margin lives in what happens after the sale — and that's exactly where we operate.' The new KONTAKTUM brand brings together years of operational know-how, a fully native-speaking team across 8 European languages, and a distributed team based in Berlin, Paris, Milan, and company also confirmed the rollout of its proprietary backend management interface, internally known as SignalDesk — a platform that allows wellness brand operators to monitor backend flows, agent performance, and reactivation ROI in real time. This level of visibility is rare in the post-purchase ecosystem, especially in multilingual markets. With GDPR-compliant infrastructure and a white-label approach, KONTAKTUM acts as the invisible layer behind the most profitable wellness brands in the region. Brands remain in full control of the customer experience, while KONTAKTUM ensures that revenue is recovered, retained, and scaled silently in the background. The split from BERGER KOMMUNIKATION also comes with internal expansion: KONTAKTUM now manages over 1.8 million customer records per quarter, and the team has grown by over 60% in the past six months. 'We're not an agency. We're infrastructure,' says the KONTAKTUM operations team. 'That means brands plug us in and see the numbers move — quietly and consistently.' Although no client names have been disclosed, industry insiders confirm KONTAKTUM is currently working with multiple top-5 EU advertisers in the wellness space, handling full backend delivery for both new and recurring customer flows. For wellness brands looking to improve retention, reduce refunds, or build a backend that actually converts — KONTAKTUM appears to be the new name to know. Media Contact:Felix Hoffmanpress@ Disclaimer: This press release is provided by the Kontaktum. The statements, views, and opinions expressed in this content are solely those of the content provider and do not necessarily reflect the views of this media platform or its publisher. We do not endorse, verify, or guarantee the accuracy, completeness, or reliability of any information presented. This content is for informational purposes only. Neither the media platform nor the publisher shall be held responsible for any fraudulent activities, misrepresentations, or financial losses arising from the content of this press release. In the event of any legal claims or charges against this article, we accept no liability or responsibility. Globenewswire does not endorse any content on this page. Legal Disclaimer: This media platform provides the content of this article on an "as-is" basis, without any warranties or representations of any kind, express or implied. We do not assume any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information presented herein. Any concerns, complaints, or copyright issues related to this article should be directed to the content provider mentioned above. Photos accompanying this announcement are available at in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data